OpGen Q1 Revenues Drop 38 Percent

May 07, 2020

|

NEW YORK ─ OpGen announced after the close of the market on Thursday a 38 percent year-over-year drop in revenues for the first quarter of 2020.

For the three months ended March 31, OpGen's revenues fell to $617,000 from $1 million in Q1 2019, in line with preliminary revenues reported in April.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Keep It (Partly) Virtual

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

For Cross-Protection

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Proteomics of Severity

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

Genome Biology Papers on Regulatory Element, Single-Cell Integration, Sequence Simulation Tools

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.

Featured White Papers

Congenica Enables Five Minute Diagnosis of Previously Unsolved Case

Congenica CNV Calling for Exomes Whitepaper

Congenica Splice Site Finder White Paper

Expediting an Accurate Diagnosis through Streamlined Clinical Workflows

Mar

11

Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar

16

Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community.

Mar

17

Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar

18

Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Viruses mutate as they strive to thrive in response to selective pressures.

Menu

OpGen Q1 Revenues Drop 38 Percent

To read the full story....

Breaking News

Olink Files For Public Offering in US

Qiagen MDx Sample Processing Platform Garners CE-IVD Mark

Tempus, Texas Oncology Subsidiary Form Data-Focused Precision Oncology Partnership

ERS Genomics Licenses CRISPR Patents to Otsuka Pharmaceutical

Human Pangenome Reference Consortium Releases Data From 30 Genomes

MDxHealth 2020 Revenues Up 57 Percent

The Scan

Keep It (Partly) Virtual

For Cross-Protection

Proteomics of Severity

Genome Biology Papers on Regulatory Element, Single-Cell Integration, Sequence Simulation Tools

Featured White Papers

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

What's Popular?

Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service

Guardant360 CDx Receives CE Mark for Tumor Mutational Profiling and Tagrisso CDx Use

Hologic Acquires European MDx Firm Diagenode for Approximately $159M

German Nucleic Acid Sample Prep Startup Rides COVID-19 Testing, Automation Waves

Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year

Sponsorships